Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated October 10, 2019, reports on the results of an Extraordinary General Meeting of Shareholders held by Entera Bio Ltd. on October 3, 2019. The filing serves to disclose shareholder voting outcomes regarding executive compensation and corporate governance amendments.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
Shareholders approved three material resolutions:
- Ratification of compensation terms for Chief Executive Officer Adam Gridley, effective August 5, 2019.
- Ratification of amended compensation terms for Dr. Phillip Schwartz, effective June 24, 2019.
- Amendment to the Articles of Association to increase the maximum number of directors from the previous limit to ten.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, market outlook, or specific risk factors. The document is a procedural report confirming the approval of the proposals detailed in the Proxy Statement filed on August 29, 2019.
Key Facts for Investor Verification
- Verify the specific compensation details for Adam Gridley and Dr. Phillip Schwartz in the Proxy Statement (Exhibit 99.1) referenced in this filing.
- Confirm the effective dates of the compensation changes (August 5, 2019, and June 24, 2019, respectively).
- Note the structural change allowing the Board of Directors to expand to a maximum of ten members.